SAN FRANCISCO, March 29, 2017 /PRNewswire/ -- Spiral Therapeutics, Inc. today announced the signature of an option agreement
"We are very pleased to acquire the opportunity to develop BN201 and BN119 for inner ear disorders and build on Bionure's excellent pre-clinical work around its candidates," said Hugo Peris, founder and CEO of Spiral Therapeutics. "This agreement will accelerate Spiral's vision to become a leading player in the fast-growing inner ear space."
"Spiral has rapidly built strong expertise in the otology field since its foundation last year," said Albert Zamora, CEO of Bionure. "We are pleased to partner with Spiral in progressing our drugs in this important therapeutic area with many unmet medical needs."
About BN201 and BN119
Bionure's compounds BN201 and BN119 are two SGK agonists with remyelinating and neuroprotective activity. Bionure has developed BN201 for the treatment of rare ophthalmic indications associated with multiple sclerosis and expects to receive Clinical Trial Authorization for BN201 in the UK in Q2 2017. BN201 and BN119 could be useful in preventing and treating debilitating inner ear disorders, like sensorineural hearing loss.
Bionure is a late-preclinical drug development company based in Barcelona, Spain focused on developing first-in-class SGK agonists for the treatment of rare ophthalmic diseases. Bionure's lead candidate BN201 is a small molecule, new chemical entity that promotes neuroprotection and remyelination. Bionure plans to start clinical trials in 2017. www.bionure.com
About Spiral Therapeutics
Spiral Therapeutics is a late stage preclinical company focused on the development of first-in-class products targeting inner ear disorders. Spiral's lead candidate LPT99 for prevention of hearing loss is expected to reach clinical stage in 2018. Spiral is headquartered in San Francisco, CA and has an R&D office in Barcelona, Spain. www.spiraltx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spiral-therapeutics-acquires-an-exclusive-option-to-develop-two-neuroprotective-agents-for-the-treatment-of-inner-ear-disorders-300430547.html
SOURCE Spiral Therapeutics, Inc.
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All